DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge

Vaccine

Volumn 28, Issue 47, 2010, Pages 7483-7491

  Kask, Angela Shaulov ^a   Chen, Xianfeng ^b   Marshak, Joshua O ^a   Dong, Lichun ^a   Saracino, Misty ^a   Chen, Dexiang ^c   Jarrahian, Courtney ^c   Kendall, Mark A ^b   Koelle, David M ^a,d,e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c PATH   (United States)

^d BENAROYA RESEARCH INSTITUTE   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

DNA vaccine; Herpes simplex virus; Microprojection; Skin

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN D; IMMUNOGLOBULIN G;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG DELIVERY SYSTEM; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; IMMUNOGENICITY; INTERFERON PRODUCTION; MOUSE; NANOPATCH; NONHUMAN; PRIORITY JOURNAL; SKIN PROTECTION; VACCINATION; VIRUS REPLICATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIBODIES, VIRAL; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES; VACCINES, DNA; VAGINA; VIRUS REPLICATION;

EID: 77958163907     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.014     Document Type: Article

References (48)

1. Koelle D.M., Corey L. Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med 2008, 59:381-395.
2. Corey L., Wald A., Patel R., Sacks S.L., Tyring S.K., Warren T., et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004 Jan, 350(1):11-20.
3. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002 Nov, 347(21):1652-1661.
4. Stanberry L.R., Rosenthal S.L. Progress in vaccines for sexually transmitted diseases. Infect Dis Clin North Am 2005 Jun, 19(2):477-490. xi.
5. Balachandran N., Bacchetti S., Rawls W.E. Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2. Infect Immun 1982 Sep, 37(3):1132-1137.
6. Kim M., Taylor J., Sidney J., Mikloska Z., Bodsworth N., Lagios K., et al. Immunodominant epitopes in herpes simplex virus type 2 glycoprotein D are recognized by CD4 lymphocytes from both HSV-1 and HSV-2 seropositive subjects. J Immunol 2008 Nov, 181(9):6604-6615.
7. Koelle D.M., Liu Z., McClurkan C.L., Cevallos R.C., Vieira J., Hosken N.A., et al. Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. Proc Natl Acad Sci U S A 2003 Oct, 100(22):12899-12904.
8. Dolan A., Jamieson F.E., Cunningham C., Barnett B.C., McGeoch D.J. The genome sequence of herpes simplex virus type 2. J Virol 1998 Mar, 72(3):2010-2021.
9. McGeoch D.J., Dolan A., Donald S., Brauer D.H. Complete DNA sequence of the short repeat region in the genome of herpes simplex virus type 1. Nucleic Acids Res 1986 Feb, 14(4):1727-1745.
10. Spear P.G. Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol 2004 May, 6(5):401-410.
11. Cattamanchi A., Posavad C.M., Wald A., Baine Y., Moses J., Higgins T.J., et al. Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin Vaccine Immunol 2008 Nov, 15(11):1638-1643.
12. Redding L., Weiner D.B. DNA vaccines in veterinary use. Expert Rev Vaccines 2009 Sep, 8(9):1251-1276.
13. Harari A., Bart P.A., Stohr W., Tapia G., Garcia M., Medjitna-Rais E., et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008 Jan, 205(1):63-77.
14. Wang S., Kennedy J.S., West K., Montefiori D.C., Coley S., Lawrence J., et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008 Jul, 26(31):3947-3957.
15. MacGregor R.R., Boyer J.D., Ugen K.E., Lacy K.E., Gluckman S.J., Bagarazzi M.L., et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998 Jul, 178(1):92-100.
16. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998 Oct, 282(5388):476-480.
17. Lu S. Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccin 2008 Nov-Dec, 4(6):449-452.
18. Lu S., Wang S., Grimes-Serrano J.M. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 2008 Mar, 7(2):175-191.
19. Kendall M. Engineering of needle-free physical methods to target epidermal cells for DNA vaccination. Vaccine 2006 May, 24(21):4651-4656.
20. Gill H.S., Soderholm J., Prausnitz M.R., Sallberg M. Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine. Gene Ther 2010 Jun, 17(6):811-814.
21. Allan R.S., Waithman J., Bedoui S., Jones C.M., Villadangos J.A., Zhan Y., et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 2006 Jul, 25(1):153-162.
22. Crichton M.L., Ansaldo A., Chen X., Prow T.W., Fernando G.J., Kendall M.A. The effect of strain rate on the precision of penetration of short densely-packed microprojection array patches coated with vaccine. Biomaterials 2010 Jun, 31(16):4562-4572.
23. Fernando G.J., Chen X., Prow T.W., Crichton M.L., Fairmaid E.J., Roberts M.S., et al. Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PLoS One 2010, 5(4):e10266.
24. Chen X., Prow T.W., Crichton M.L., Jenkins D.W., Roberts M.S., Frazer I.H., et al. Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin. J Control Release 2009 Nov, 139(3):212-220.
25. Raju P.A., McSloy N., Truong N.K., Kendall M.A. Assessment of epidermal cell viability by near infrared multi-photon microscopy following ballistic delivery of gold micro-particles. Vaccine 2006 May, 24(21):4644-4647.
26. Jing L., McCaughey S.M., Davies D.H., Chong T.M., Felgner P.L., De Rosa S.C., et al. ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans. J Immunol Methods 2009 Aug, 347(1-2):36-45.
27. Watson R.J. DNA sequence of the Herpes simplex virus type 2 glycoprotein D gene. Gene 1983 Dec, 26(2-3):307-312.
28. Muller W.J., Dong L., Vilalta A., Byrd B., Wilhelm K.M., McClurkan C.L., et al. Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection. J Gen Virol 2009 May, 90(Pt 5):1153-1163.
29. Stanberry L.R., Bernstein D.I., Kit S., Myers M.G. Genital reinfection after recovery from initial genital infection with herpes simplex virus type 2 in guinea pigs. J Infect Dis 1986 Jun, 153(6):1055-1061.
30. Parr M.B., Kepple L., McDermott M.R., Drew M.D., Bozzola J.J., Parr E.L. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab Invest 1994 Mar, 70(3):369-380.
31. Wald A., Huang M.L., Carrell D., Selke S., Corey L. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis 2003 Nov, 188(9):1345-1351.
32. Malin S.A., Davis B.M., Molliver D.C. Production of dissociated sensory neuron cultures and considerations for their use in studying neuronal function and plasticity. Nat Protoc 2007, 2(1):152-160.
33. Ghiasi H., Cai S., Slanina S., Nesburn A.B., Wechsler S.L. Vaccination of mice with herpes simplex virus type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-1 challenge. Antiviral Res 1995 Oct, 28(2):147-157.
34. Kriesel J.D., Spruance S.L., Daynes R.A., Araneo B.A. Nucleic acid vaccine encoding gD2 protects mice from herpes simplex virus type 2 disease. J Infect Dis 1996 Mar, 173(3):536-541.
35. Bourne N., Milligan G.N., Schleiss M.R., Bernstein D.I., Stanberry L.R. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine 1996 Sep, 14(13):1230-1234.
36. McClements W.L., Armstrong M.E., Keys R.D., Liu M.A. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc Natl Acad Sci U S A 1996 Oct, 93(21):11414-11420.
37. Pachuk C.J., Arnold R., Herold K., Ciccarelli R.B., Higgins T.J. Humoral and cellular immune responses to herpes simplex virus-2 glycoprotein D generated by facilitated DNA immunization of mice. Curr Top Microbiol Immunol 1998, 226:79-89.
38. Sin J.I., Kim J.J., Ugen K.E., Ciccarelli R.B., Higgins T.J., Weiner D.B. Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes. Eur J Immunol 1998 Nov, 28(11):3530-3540.
39. Sin J.I., Kim J.J., Boyer J.D., Ciccarelli R.B., Higgins T.J., Weiner D.B. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J Virol 1999 Jan, 73(1):501-509.
40. Nass P.H., Elkins K.L., Weir J.P. Protective immunity against herpes simplex virus generated by DNA vaccination compared to natural infection. Vaccine 2001 Jan, 19(11-12):1538-1546.
41. Sin J.I., Kim J.J., Arnold R.L., Shroff K.E., McCallus D., Pachuk C., et al. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. J Immunol 1999 Mar, 162(5):2912-2921.
42. Sin J.I., Kim J., Dang K., Lee D., Pachuk C., Satishchandran C., et al. LFA-3 plasmid DNA enhances Ag-specific humoral- and cellular-mediated protective immunity against herpes simplex virus-2 in vivo: involvement of CD4+ T cells in protection. Cell Immunol 2000 Jul, 203(1):19-28.
43. Zhu Q., Zarnitsyn V.G., Ye L., Wen Z., Gao Y., Pan L., et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci U S A 2009 May, 106(19):7968-7973.
44. Frech S.A., Dupont H.L., Bourgeois A.L., McKenzie R., Belkind-Gerson J., Figueroa J.F., et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008 Jun, 371(9629):2019-2025.
45. Ishii Y., Nakae T., Sakamoto F., Matsuo K., Quan Y.S., Kamiyama F., et al. A transcutaneous vaccination system using a hydrogel patch for viral and bacterial infection. J Control Release 2008 Oct 21, 131(2):113-120.
46. Kramer M., Riley J., Spoering A., Coen D., Knipe D. Effect of immunization on herpes simplex virus type 1 latent infection in the trigeminal ganglion. Curr Eye Res 2003 Mar-Apr, 26(3-4):185-194.
47. Ghiasi H., Nesburn A.B., Wechsler S.L. Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein. Vaccine 1996 Feb, 14(2):107-112.
48. Hoshino Y., Dalai S.K., Wang K., Pesnicak L., Lau T.Y., Knipe D.M., et al. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol 2005 Jan, 79(1):410-418.